Moreton Applied – Research Theme Primer

Executive Summary

Artificial intelligence in aged and disability care is transitioning from isolated pilot projects toward integrated ecosystems that combine machine learning, robotics, IoT, and generative AI. Evidence now demonstrates meaningful benefits in safety, mood, diagnostics, and personalisation – but most systems remain pilot-level, disease-specific, and face significant ethical, equity, and implementation hurdles.

This primer maps the current state of the art against Moreton Applied’s R&D and commercialisation interests, identifying where the field is mature enough for product development, where foundational gaps create opportunities, and where ethical and market risks demand caution.

---

1. Technology Landscape

1.1 Monitoring, Fall Detection & Activity Recognition

Deep learning applied to vision and sensor data now achieves high accuracy in detecting falls and recognising daily activities within home and ambient-assisted-living settings, though deployment and privacy challenges remain substantial.

Commercialisation signal: Strong. Hardware commoditisation (cameras, wearables, edge devices) lowers the barrier; the value layer is in the software and integration. Privacy-preserving architectures (on-device inference, federated learning) are a differentiator, not just a compliance requirement.

1.2 Diagnostics & Risk Prediction

ML and deep learning models for dementia screening, stroke detection, infection identification, and mortality risk stratification in long-term care have reported AUCs up to approximately 0.98 with clear risk-group separation.

Commercialisation signal: Moderate-to-strong, but regulatory pathway is long. Most models are condition-specific and trained on narrow cohorts. The opportunity lies in multi-condition platforms validated across diverse aged-care populations.

1.3 Social & Assistive Robotics

Companion and social robots (e.g., PARO) have demonstrated reductions in agitation, depression, and loneliness, while physical-assist robots address mobility needs for bedridden or disabled users.

Commercialisation signal: Niche but growing. Unit economics remain challenging. Software-defined companionship (voice/avatar agents on commodity hardware) may outpace purpose-built robotics in near-term uptake.

1.4 Rehabilitation & Disability Support

AI-driven personalised rehabilitation – including brain-computer interfaces, wearables, and ML/DL for stroke recovery – is extending the reach and precision of therapeutic programs.

Commercialisation signal: Strong where reimbursement pathways exist. Remote and hybrid rehab models accelerated by COVID-era policy shifts remain viable. Adaptive difficulty and real-time feedback loops are high-value differentiators.

---

2. Enabling Architecture Trends

2.1 IoT & Edge Intelligence

Sensor networks and edge computing enable real-time monitoring of falls, vital signs, and behavioural patterns, reducing latency and improving privacy in long-term care and smart-home environments.

R&D implication: Edge-first design should be the default assumption for any product targeting in-home or residential aged care, both for latency and for data-sovereignty compliance.

2.2 Generative AI

Generative models are being applied in two modes: data synthesis (e.g., GANs to augment rare-condition datasets for smart-home scenarios) and conversational or cognitive assistance for older adults and caregivers.

R&D implication: The conversational-assistant opportunity is large but carries unique safety risks in vulnerable populations. Synthetic data generation is a lower-risk, higher-leverage near-term use case for accelerating model development where real-world data is scarce.

2.3 Clinical Decision Support

AI tools for dementia care, infection management, and mental health are improving diagnostic accuracy, antimicrobial stewardship, and treatment planning, though most remain narrowly scoped.

R&D implication: Integration into existing clinical workflows – not standalone dashboards – is the critical design constraint. Tools that reduce cognitive load for time-poor care staff will outperform those that add new screens.

---

3. Barriers, Risks & Ethical Constraints

3.1 Evidence Gaps

Small samples, short trial durations, condition-specific focus (especially dementia), under-representation of frail adults, lack of explainability, and insufficient real-world validation are pervasive across the literature.

3.2 Ethical & Equity Risks

Algorithmic bias, privacy and security vulnerabilities, inequitable access, and generative-AI-specific risks such as manipulation and scam facilitation require proactive governance.

3.3 Implementation & Market Barriers

Cost, interoperability, clinician trust, and workforce shortages are persistent obstacles. Critically, AI cannot solve structural staffing problems – it must be positioned as a force-multiplier for existing care capacity, not a replacement.

3.4 Emerging Governance Frameworks

Ethics checklists and implementation-science-guided pathways for safe integration are beginning to formalise, creating both compliance obligations and market credibility opportunities for early adopters.